{"pmid":32369479,"title":"Antibody-based therapies for COVID-19: Can Europe move faster?","text":["Antibody-based therapies for COVID-19: Can Europe move faster?","Michel Goldman and colleagues call on the European medical and scientific community to coordinate efforts on immunotherapy-based approaches to coronavirus.","PLoS Med","Kazatchkine, Michel D","Goldman, Michel","Vincent, Jean-Louis","32369479"],"abstract":["Michel Goldman and colleagues call on the European medical and scientific community to coordinate efforts on immunotherapy-based approaches to coronavirus."],"journal":"PLoS Med","authors":["Kazatchkine, Michel D","Goldman, Michel","Vincent, Jean-Louis"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369479","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1371/journal.pmed.1003127","topics":["General Info"],"weight":1,"_version_":1666138496169934849,"score":9.490897,"similar":[{"pmid":32424062,"title":"Can China's 'standard of care' for COVID-19 be replicated in Europe?","text":["Can China's 'standard of care' for COVID-19 be replicated in Europe?","The Director-General of the WHO has suggested that China's approach to the COVID-19 crisis could be the standard of care for global epidemics. However, as remarkable as the Chinese strategy might be, it cannot be replicated in other countries and certainly not in Europe. In Europe, there is a distribution of power between the European Union and its member states. In contrast, China's political power is concentrated in the central government. This enables it to take immediate measures that affect the entire country, such as massive quarantines or closing borders. Moreover, the Chinese legal framework includes restrictions on privacy and other human rights that are unknown in Europe. In addition, China has the technological power to easily impose such restrictions. In most European countries, that would be science fiction. These conditions have enabled China to combat epidemics like no other country can. However, the WHO might have been overoptimistic. The Chinese standard of care for treating COVID-19 also raises problematic issues for human rights, and the real consequences of these actions remain to be seen.","J Med Ethics","Raposo, Vera Lucia","32424062"],"abstract":["The Director-General of the WHO has suggested that China's approach to the COVID-19 crisis could be the standard of care for global epidemics. However, as remarkable as the Chinese strategy might be, it cannot be replicated in other countries and certainly not in Europe. In Europe, there is a distribution of power between the European Union and its member states. In contrast, China's political power is concentrated in the central government. This enables it to take immediate measures that affect the entire country, such as massive quarantines or closing borders. Moreover, the Chinese legal framework includes restrictions on privacy and other human rights that are unknown in Europe. In addition, China has the technological power to easily impose such restrictions. In most European countries, that would be science fiction. These conditions have enabled China to combat epidemics like no other country can. However, the WHO might have been overoptimistic. The Chinese standard of care for treating COVID-19 also raises problematic issues for human rights, and the real consequences of these actions remain to be seen."],"journal":"J Med Ethics","authors":["Raposo, Vera Lucia"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32424062","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/medethics-2020-106210","keywords":["health promotion","legal aspects","public health ethics","public policy"],"locations":["China","Chinese","China","Chinese","China","China","Chinese","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1667252837800738816,"score":51.321552},{"pmid":32415272,"title":"Connecting data, tools and people across Europe: ELIXIR's response to the COVID-19 pandemic.","text":["Connecting data, tools and people across Europe: ELIXIR's response to the COVID-19 pandemic.","ELIXIR, the European research infrastructure for life science data, provides open access to data, tools and workflows in the response to the COVID-19 pandemic. ELIXIR's 23 nodes have reacted swiftly to support researchers in their combined efforts against the pandemic setting out three joint priorities: 1. Connecting national COVID-19 data platforms to create federated European COVID-19 Data Spaces; 2. Fostering good data management to make COVID-19 data open, FAIR and reusable over the long term; 3. Providing open tools, workflows and computational resources to drive reproducible and collaborative science. ELIXIR's strategy is based on the support given by our national nodes - collectively spanning over 200 institutes - to research projects and on partnering with community initiatives to drive development and adoption of good data practice and community driven standards. ELIXIR Nodes provide support activities locally and internationally, from provisioning compute capabilities to helping collect viral sequence data from hospitals. Some Nodes have prioritised access to their national cloud and compute facilities for all COVID-19 research projects, while others have developed tools to search, access and share all data related to the pandemic in a national healthcare setting.","Eur J Hum Genet","Blomberg, Niklas","Lauer, Katharina B","32415272"],"abstract":["ELIXIR, the European research infrastructure for life science data, provides open access to data, tools and workflows in the response to the COVID-19 pandemic. ELIXIR's 23 nodes have reacted swiftly to support researchers in their combined efforts against the pandemic setting out three joint priorities: 1. Connecting national COVID-19 data platforms to create federated European COVID-19 Data Spaces; 2. Fostering good data management to make COVID-19 data open, FAIR and reusable over the long term; 3. Providing open tools, workflows and computational resources to drive reproducible and collaborative science. ELIXIR's strategy is based on the support given by our national nodes - collectively spanning over 200 institutes - to research projects and on partnering with community initiatives to drive development and adoption of good data practice and community driven standards. ELIXIR Nodes provide support activities locally and internationally, from provisioning compute capabilities to helping collect viral sequence data from hospitals. Some Nodes have prioritised access to their national cloud and compute facilities for all COVID-19 research projects, while others have developed tools to search, access and share all data related to the pandemic in a national healthcare setting."],"journal":"Eur J Hum Genet","authors":["Blomberg, Niklas","Lauer, Katharina B"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32415272","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1038/s41431-020-0637-5","locations":["Nodes"],"topics":["Prevention"],"weight":1,"_version_":1666991242719789056,"score":45.936455},{"pmid":32156332,"pmcid":"PMC7068161","title":"Potential scenarios for the progression of a COVID-19 epidemic in the European Union and the European Economic Area, March 2020.","text":["Potential scenarios for the progression of a COVID-19 epidemic in the European Union and the European Economic Area, March 2020.","Two months after the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the possibility of established and widespread community transmission in the European Union and European Economic Area (EU/EEA) is becoming more likely. We provide scenarios for use in preparedness for a possible widespread epidemic. The EU/EEA is moving towards the 'limited sustained transmission' phase. We propose actions to prepare for potential mitigation phases and coordinate efforts to protect the health of citizens.","Euro Surveill","Johnson, Helen C","Gossner, Celine M","Colzani, Edoardo","Kinsman, John","Alexakis, Leonidas","Beaute, Julien","Wurz, Andrea","Tsolova, Svetla","Bundle, Nick","Ekdahl, Karl","32156332"],"abstract":["Two months after the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the possibility of established and widespread community transmission in the European Union and European Economic Area (EU/EEA) is becoming more likely. We provide scenarios for use in preparedness for a possible widespread epidemic. The EU/EEA is moving towards the 'limited sustained transmission' phase. We propose actions to prepare for potential mitigation phases and coordinate efforts to protect the health of citizens."],"journal":"Euro Surveill","authors":["Johnson, Helen C","Gossner, Celine M","Colzani, Edoardo","Kinsman, John","Alexakis, Leonidas","Beaute, Julien","Wurz, Andrea","Tsolova, Svetla","Bundle, Nick","Ekdahl, Karl"],"date":"2020-03-12T11:00:00Z","year":2020,"_id":"32156332","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.2807/1560-7917.ES.2020.25.9.2000202","keywords":["covid-19","europe","sars-cov-2","coronavirus","pandemic","preparedness"],"topics":["Prevention"],"weight":1,"_version_":1666138492684468224,"score":45.792824},{"pmid":32184209,"title":"Covid-19: trainees will not move jobs in April.","text":["Covid-19: trainees will not move jobs in April.","BMJ","Rimmer, Abi","32184209"],"journal":"BMJ","authors":["Rimmer, Abi"],"date":"2020-03-19T11:00:00Z","year":2020,"_id":"32184209","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1136/bmj.m1088","topics":["General Info"],"weight":1,"_version_":1666138492534521859,"score":45.38797},{"pmid":32134278,"title":"Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).","text":["Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).","Last decade witnessed the outbreak of many life-threatening human pathogens including Nipah, Ebola, Chikungunya, Zika, Middle East respiratory syndrome coronavirus (MERS-CoV), Severe Acute respiratory syndrome coronavirus (SARS-CoV) and more recently novel coronavirus (2019-nCoV or SARS-CoV-2). The disease condition associated with novel coronavirus, referred to as Coronavirus disease (COVID-19). The emergence of novel coronavirus in 2019 in Wuhan, China marked the third highly pathogenic coronavirus infecting humans in the 21st century. The continuing emergence of coronaviruses at regular intervals poses a significant threat to human health and economy. Ironically, even after a decade of research on coronavirus, still there are no licensed vaccines or therapeutic agents to treat coronavirus infection which highlights an urgent need to develop effective vaccines or post-exposure prophylaxis to prevent future epidemics. Several clinical, genetic and epidemiological features of COVID-19 resemble SARS-CoV infection. Hence, the research advancements on SARS-CoV treatment might help scientific community in quick understanding of this virus pathogenesis and develop effective therapeutic/prophylactic agents to treat and prevent this infection. Monoclonal antibodies represent the major class of biotherapeutics for passive immunotherapy to fight against viral infection. The therapeutic potential of monoclonal antibodies has been well recognized in the treatment of many diseases. Here, we summarize the potential monoclonal antibody based therapeutic intervention for COVID-19 by considering the existing knowledge on the neutralizing monoclonal antibodies against similar coronaviruses SARS-CoV and MERS-CoV. Further research on COVID-19 pathogenesis could identify appropriate therapeutic targets to develop specific anti-virals against this newly emerging pathogen.","Asian Pac J Allergy Immunol","Shanmugaraj, Balamurugan","Siriwattananon, Konlavat","Wangkanont, Kittikhun","Phoolcharoen, Waranyoo","32134278"],"abstract":["Last decade witnessed the outbreak of many life-threatening human pathogens including Nipah, Ebola, Chikungunya, Zika, Middle East respiratory syndrome coronavirus (MERS-CoV), Severe Acute respiratory syndrome coronavirus (SARS-CoV) and more recently novel coronavirus (2019-nCoV or SARS-CoV-2). The disease condition associated with novel coronavirus, referred to as Coronavirus disease (COVID-19). The emergence of novel coronavirus in 2019 in Wuhan, China marked the third highly pathogenic coronavirus infecting humans in the 21st century. The continuing emergence of coronaviruses at regular intervals poses a significant threat to human health and economy. Ironically, even after a decade of research on coronavirus, still there are no licensed vaccines or therapeutic agents to treat coronavirus infection which highlights an urgent need to develop effective vaccines or post-exposure prophylaxis to prevent future epidemics. Several clinical, genetic and epidemiological features of COVID-19 resemble SARS-CoV infection. Hence, the research advancements on SARS-CoV treatment might help scientific community in quick understanding of this virus pathogenesis and develop effective therapeutic/prophylactic agents to treat and prevent this infection. Monoclonal antibodies represent the major class of biotherapeutics for passive immunotherapy to fight against viral infection. The therapeutic potential of monoclonal antibodies has been well recognized in the treatment of many diseases. Here, we summarize the potential monoclonal antibody based therapeutic intervention for COVID-19 by considering the existing knowledge on the neutralizing monoclonal antibodies against similar coronaviruses SARS-CoV and MERS-CoV. Further research on COVID-19 pathogenesis could identify appropriate therapeutic targets to develop specific anti-virals against this newly emerging pathogen."],"journal":"Asian Pac J Allergy Immunol","authors":["Shanmugaraj, Balamurugan","Siriwattananon, Konlavat","Wangkanont, Kittikhun","Phoolcharoen, Waranyoo"],"date":"2020-03-06T11:00:00Z","year":2020,"_id":"32134278","source":"PubMed","week":"202010|Mar 02 - Mar 08","doi":"10.12932/AP-200220-0773","locations":["Chikungunya","Zika","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138490707902464,"score":44.46528}]}